CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
Rhea-AI Summary
CDT Equity (Nasdaq: CDT) reported receipt of a Nasdaq deficiency letter after not timely filing its Form 10-Q for the quarter ended March 31, 2026, as required by Nasdaq Listing Rule 5250(c)(1).
The notice does not immediately affect listing or trading. CDT has until July 20, 2026 to submit a compliance plan and expects to file the Form 10-Q once its review is complete.
Positive
- No immediate effect on listing or trading of CDT securities
- Nasdaq granted time until July 20, 2026 to submit compliance plan
- Company anticipates filing the delayed Form 10-Q after review completion
Negative
- Nasdaq deficiency letter for late Form 10-Q filing
- Non-compliance with Nasdaq Listing Rule 5250(c)(1) periodic filing requirement
News Market Reaction – CDT
In the May 29 session, CDT gained 9.46%, reflecting a notable positive market reaction. Argus tracked a peak move of +177.5% during that session. Argus tracked a trough of -13.7% from its starting point during tracking. Our momentum scanner triggered 91 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 105.7x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Canadian patent win | Positive | +24.4% | Canadian patent for AZD5904 in male infertility, reinforcing IP coverage. |
| May 07 | Cystic fibrosis IP | Positive | -8.0% | Sarborg SOM patent filing for cystic fibrosis compounds; CDT holds 20% stake. |
| May 06 | Global patent phase | Positive | +8.7% | AZD5904 moved into PCT global patent phase with partnering discussions initiated. |
| Apr 16 | Strategy update | Neutral | -24.4% | Outlined multi-pathway value strategy across pharma assets, IP, and AI discovery. |
| Apr 07 | AI PRISM framework | Positive | +6.8% | Sarborg PRISM AI framework publication; CDT highlighted 20% equity interest. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent IP- and strategy-focused news has produced volatile, mixed reactions, with some patent milestones aligning with positive moves while other updates sold off despite constructive narratives.
Over the last few months, CDT has focused on intellectual property and strategic positioning. On May 27, 2026, a Canadian patent for AZD5904 in male infertility coincided with a 24.39% gain. Earlier in May, a new cystic fibrosis SOM patent linked to its 20% Sarborg stake saw a -7.96% move, while advancing AZD5904 into the PCT global patent phase drove an 8.65% rise. April AI- and IP-driven updates produced both gains and losses, underscoring inconsistent market reactions to otherwise generally positive developments as this compliance notice arrives.
Key Terms
form 10-q regulatory
nasdaq listing rule 5250(c)(1) regulatory
periodic filing requirement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that the Company received a written notice (“Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2026 indicating that the Company did not timely file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”), as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”). The Notice does not have an immediate effect on the listing or trading of the Company’s securities. The Notice provided that under Nasdaq rules, the Company has until July 20, 2026 to submit a plan to regain compliance with the Periodic Filing Requirement. The Company anticipates filing its Form 10-Q as soon as the review process of the current draft is complete, thereby regaining compliance with the Periodic Filing Requirement.
About CDT Equity Inc.
CDT Equity Inc. (Nasdaq: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the effect that the Notice may have on the Company’s securities; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors
CDT Equity Inc.
Info@cdtequity.com
